Spina bifida is one of the congenital neural tube defects that can lead to loss of bladder control, also known as neurogenic bladder. This can lead to recurrent urinary tract infections and subsequent renal function decline if not properly managed. Proper management may include pharmacological care that aims to prevent improper drainage of the bladder directly by utilizing agents such as anticholinergics, urinary antispasmodics, and botulism toxins. In addition to direct care, patients with neurogenic bladder also may require bowel regimens because of concurrent instances of neurogenic bowels.
AmarkP.BussmanG.EksborgS. (1998). Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children. European Urology, 34, 148–153.
2.
AslanA. R.KoganB. A. (2002). Conservative management in neurogenic bladder dysfunction. Current Opinion in Urology, 12(6), 473–477. 10.1097/00042307-200211000-00005
3.
BeierwaltesP.ChurchP.GordonT.AmbartsumyanL. (2020). Bowel function and care: Guidelines for the care of people with spina bifida. Journal of Pediatric Rehabilitation Medicine, 13(4), 491–498.
4.
DashV.BawaM.MahajanJ. K.KanojiaR. P.SamujhR.RaoK. L. (2016). Role of gabapentin and anticholinergics in management of neurogenic bladder after repair of spina bifida—A randomized controlled study. Journal of Pediatric Surgery, 51(12), 2025–2029.10.1016/j.jpedsurg.2016.09.030
5.
de JongT. P.ChrzanR.KlijnA. J.DikP. (2008). Treatment of the neurogenic bladder in spina bifida. Pediatric Nephrology, 23(6), 889–896. 10.1007/s00467-008-0780-7
6.
FowlerC. J.GriffithsD.de GroatW. C. (2008). The neural control of micturition. Nature Reviews. Neuroscience, 9(6), 453–466. 10.1038/nrn2401
7.
HascoetJ.PeyronnetB.ForinV.BaronM.CaponG.PrudhommeT.AllenetC.TournierS.MaurinC.CornuJ. N.BoualiO.PeycelonM.ArnaudA.Renaux-PetelM.LiardA.KarsentyG.ManuntaA.GameX. (2018). Intradetrusor injections of botulinum toxin type a in children with spina bifida: A multicenter study. Urology, 116, 161–167. 10.1016/j.urology.2018.02.033
8.
JosephD. B.BaumM. A.TanakaS. T.FrimbergerD. C.MisseriR.KhavariR.BaillieS.YerkesE. B.WoodH. (2020). Urologic guidelines for the care and management of people with spina bifida. Journal of Pediatric Rehabilitation Medicine, 13(4), 479–489.
9.
KaeferM.PabbyA.KellyM.DarbeyM.BauerS. B. (1999). Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomeningocele. The Journal of Urology, 162, 1068–1071.
10.
KasabianN. G.BauerS. B.DyroF. M.ColodnyA. H.MandellJ.RetikA. B. (1992). The prophylactic value of clean intermittent catheterization and anticholinergic medication in newborns and infants with myelodysplasia at risk of developing urinary tract deterioration. American Journal of Diseases of Children, 146(7), 840–843. 10.1001/archpedi.1992.02160190072024
11.
KaskM.RintalaR.TaskinenS. (2014). Effect of onabotulinumtoxinA treatment on symptoms and urodynamic findings in pediatric neurogenic bladder. Journal of Pediatric Urology, 10(2), 280–283. 10.1016/j.jpurol.2013.09.004
12.
KochakarnW.Ratana-OlarnK.LertsithichaiP.RoongreungsilpU. (2004). Follow-up of long-term treatment with clean intermittent catheterization for neurogenic bladder in children. Asian Journal of Surgery, 272, 134–136. 10.1016/S1015-9584(09)60327-4
13.
KoffS. A.GigaxM. R.JayanthiV. R. (2005). Nocturnal bladder emptying: A simple technique for reversing urinary tract deterioration in children with neurogenic bladder. The Journal of Urology, 174(4, Pt. 2), 1629–1632. 10.1097/01.ju.0000176418.24299.ff
14.
KuteesaW.MooreK. H. (2006). Anticholinergic drugs for overactive bladder. Australian Prescriber, 29, 22–24. 10.
18773/austprescr.2006.012
15.
LeeJ. H.KimK. R.LeeY. S.HanS. W.KimK. S.SongS. H.BaekM.ParkK. (2014). Efficacy, tolerability, and safety of oxybutynin chloride in pediatric neurogenic bladder with spinal dysraphism: A retrospective, multicenter, observational study. Korean Journal of Urology, 55(12), 828–833. 10.4111/kju.2014.55.12.828
16.
MadersbacherH.JilgG. (1991). Control of detrusor hyperreflexia by the intravesical instillation of oxybutynin hydrochloride. Paraplegia, 29, 84–90.
17.
MantelC.CarlinK.ThomasK. (2019). Daily enemas for pediatric bowel management. Journal of Pediatric Surgical Nursing, 8(3), 79–85.
18.
MüllerT.ArbeiterK.AufrichtC. (2002). Renal function in meningomyelocele: Risk factors, chronic renal failure, renal replacement therapy and transplantation. Current Opinion in Urology, 12(6), 479–484.
19.
PhillipsL. A.BurtonJ. M.EvansS. H. (2017). Spina bifida management. Current Problems in Pediatric and Adolescent Health Care, 47(7), 173–177. 10.1016/j.cppeds.2017.06.007
20.
SagerC.BurekC.DuránV.CorbettaJ. P.WellerS.JuanB.LópezJ. C. (2012). Pharmacotherapy in pediatric neurogenic bladder intravesical botulinum toxin type A. International Scholarly Research Notices, 2012, 763159. 10.5402/2012/763159
21.
StoffelJ. T. (2016). Detrusor sphincter dyssynergia: A review of physiology, diagnosis, and treatment strategies. Translational Andrology Urology, 5(1), 127–135. 10.3978/j.issn.2223-4683.2016.01.08
22.
TanakaS. T.ParamsothyP.ThibadeauJ.WienerJ. S.JosephD. B.ChengE. Y.TuD.AustinC.KohC. J.WallisM. C.WalkerW. O.SmithK. A.RouthJ. C.BaumM. A. (2019). Baseline urinary imaging in infants enrolled in Urologic Management to Preserve Initial Renal Function (UMPIRE) protocol for children with spina bifida. The Journal of Urology, 201(6), 1193–1198. 10.1097/JU.0000000000000141
23.
VerpoortenC.BuyseG. M. (2008). The neurogenic bladder: Medical treatment. Pediatric Nephrology, 23(5), 717–725. 10.1007/s00467-007-0691-z
24.
WallisM. C.ParamsothyP.NewsomeK.WilliamsT.RouthJ. C.JosephD. B.ChengE.TuD.AustinJ. C.TanakaS. T.WalkerW. O.SmithK. A.BaumM. A.WienerJ. S. (2021). Incidence of urinary tract infections in newborns with spina bifida—Is antibiotic prophylaxis necessary?. The Journal of Urology, 206(1), 126–132. 10.1097/JU.0000000000001690
25.
YoshimuraN.KaihoY.MiyazatoM.YunokiT.TaiC.ChancellorM. B.TyagiP. (2008). Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn-Schmiedeberg's Archives of Pharmacology, 377, 437–448.
